Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects
Abstract Background PF-06650833 is a potent, selective inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). Two randomized, double-blind, sponsor-open phase 1 studies evaluated the safety, pharmacokinetics, and pharmacodynamics of single (SAD) and multiple ascending doses (MAD) of PF-066...
Autors principals: | Spencer I. Danto, Negin Shojaee, Ravi Shankar P. Singh, Cheryl Li, Steven A. Gilbert, Zorayr Manukyan, Iain Kilty |
---|---|
Format: | Article |
Idioma: | English |
Publicat: |
BMC
2019-12-01
|
Col·lecció: | Arthritis Research & Therapy |
Matèries: | |
Accés en línia: | https://doi.org/10.1186/s13075-019-2008-6 |
Ítems similars
-
Research and clinical updates on IRAK4 and its roles in inflammation and malignancy: themes and highlights from the 1st symposium on IRAK4 in cancer
per: Guillermo Garcia-Manero, et al.
Publicat: (2024-02-01) -
Emerging interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors or degraders as therapeutic agents for autoimmune diseases and cancer
per: Yifan Feng, et al.
Publicat: (2024-12-01) -
Afghanistan, Irak og utviklingen av USAs militærmakt
per: Ståle Ulriksen
Publicat: (2022-08-01) -
The IRAK-M death domain: a tale of three surfaces
per: Berke Gürkan, et al.
Publicat: (2024-01-01) -
Irak-Estados Unidos. Reacción de la prensa chilena y mexicana
per: Eduardo Arriagada C., et al.
Publicat: (2015-01-01)